-
EP2988131
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2988131
| EP2988131 - GENETIC MARKER FOR EARLY BREAST CANCER PROGNOSIS PREDICTION AND DIAGNOSIS, AND USE THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 09.11.2018 Database last updated on 06.07.2024 | |
| Former | Examination is in progress Status updated on 16.02.2018 | Most recent event Tooltip | 09.11.2018 | Application deemed to be withdrawn | published on 12.12.2018 [2018/50] | Applicant(s) | For all designated states Gencurix Inc. Hanhwa Bizmetro 1-cha Guro-dong 909 242 Digital-ro Guro-gu Seoul 152-733 / KR | [2016/08] | Inventor(s) | 01 /
SHIN, Young Kee (Samsung Apts. Daechi-dong) 114-1301 22 Dogok-ro 78-gil Gangnam-gu Seoul 135-968 / KR | 02 /
KIM, Young-Deug (Ssangyong Apts. Gwangyo-dong) 5-907 231 Juseung-ro, Nam-gu Incheon 402-715 / KR | 03 /
OH, Eu Sel (Bangbae-dong) 32-10 Bangbae-ro 35-gil Seocho-gu Seoul 137-830 / KR | 04 /
CHOI, Jun Young (Hahan Jugong 10 Danji Apt. Haan-dong) 1008 604 320 Haan-ro Gwangmyeong-si Gyeonggi-do 423-762 / KR | 05 /
CHO, Sang Rea (Hyoja-dong) 41-26 Jahamun-ro 24-gil Jongno-gu Seoul 110-033 / KR | [2016/08] | Representative(s) | Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE | [2016/08] | Application number, filing date | 14785227.1 | 18.04.2014 | [2016/08] | WO2014KR03384 | Priority number, date | KR20130043160 | 18.04.2013 Original published format: KR 20130043160 | [2016/08] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014171778 | Date: | 23.10.2014 | Language: | KO | [2014/43] | Type: | A1 Application with search report | No.: | EP2988131 | Date: | 24.02.2016 | Language: | EN | [2016/08] | Search report(s) | International search report - published on: | KR | 23.10.2014 | (Supplementary) European search report - dispatched on: | EP | 13.03.2017 | Classification | IPC: | G01N33/574, C12Q1/68, G01N33/53 | [2016/08] | CPC: |
C12Q1/6886 (EP,KR,US);
C12Q1/68 (KR);
C12Q1/6844 (KR);
G01N33/5308 (KR);
G01N33/57415 (EP,KR,US);
C12Q2600/118 (EP,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/08] | Title | German: | GENETISCHER MARKER FÜR FRÜHE BRUSTKREBSPROGNOSE UND DIAGNOSE SOWIE VERWENDUNG | [2016/08] | English: | GENETIC MARKER FOR EARLY BREAST CANCER PROGNOSIS PREDICTION AND DIAGNOSIS, AND USE THEREOF | [2016/08] | French: | MARQUEUR GÉNÉTIQUE POUR LA PRÉDICTION PRONOSTIQUE ET LE DIAGNOSTIC PRÉCOCES DU CANCER DU SEIN ET LEUR UTILISATION | [2016/08] | Entry into regional phase | 18.11.2015 | Translation filed | 18.11.2015 | National basic fee paid | 18.11.2015 | Search fee paid | 18.11.2015 | Designation fee(s) paid | 18.11.2015 | Examination fee paid | Examination procedure | 18.11.2015 | Examination requested [2016/08] | 26.09.2017 | Amendment by applicant (claims and/or description) | 19.02.2018 | Despatch of a communication from the examining division (Time limit: M04) | 03.07.2018 | Application deemed to be withdrawn, date of legal effect [2018/50] | 01.08.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2018/50] | Fees paid | Renewal fee | 30.04.2016 | Renewal fee patent year 03 | 01.05.2017 | Renewal fee patent year 04 | 30.04.2018 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2005001138 (ARCTURUS BIOSCIENCE INC [US], et al) [X] 1-13* claim 5; table 3 *; | [X]WO2005033699 (NCC TECHNOLOGY VENTURES PTE LT [SG], et al) [X] 1-13 * abstract *; | [X]US2006074565 (MILLER LANCE D [SG], et al) [X] 1-13 * abstract *; | [X]WO2008030845 (VERIDEX LLC [US], et al) [X] 1-13 * pages 16-17; claim 2; table 5 *; | [X]WO2011063274 (GENOMIC HEALTH INC [US], et al) [X] 1-13 * abstract *; | [X]WO2012166700 (LISANTI MICHAEL P [US], et al) [X] 1-13 * claims 14-17,31 *; | [X] - MEHRA M R ET AL, "131: Gene expression and prediction of early cardiac allograft rejection: Discovery of a gene-based corticosteroid efficacy measure", JOURNAL OF HEART AND LUNG TRANSPLANTATION, MOSBY-YEAR BOOK, INC., ST LOUIS, MO, US, vol. 26, no. 2, doi:10.1016/J.HEALUN.2006.11.147, ISSN 1053-2498, (20070201), pages S106 - S107, (20070201), XP027495562 [X] 5,6,12 * abstract * DOI: http://dx.doi.org/10.1016/j.healun.2006.11.147 | International search | [Y]US2008206769 (LAU KIT [US], et al); | [Y]KR20090088757 (SEOUL NAT UNIV IND FOUNDATION [KR]); | [A]US2010035240 (JIANG WEN GUO [GB]); | [A]KR20110110031 (SNU R& DB FOUNDATION [KR]); | [X]KR20120079295 (GENCURIX INC [KR]); | [A] - LE PAGE, CECILE ET AL., "BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated with Higher Tumor Infiltrating T Cells and a Better Prognosis", PLOS ONE, (2012), vol. 7, no. 6, page E38541, XP055286966 DOI: http://dx.doi.org/10.1371/journal.pone.0038541 | by applicant | KR20120079295 | WO2012093821 | - CHANG, H.Y. ET AL., "Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds", PLOSBIOL, (2004), vol. 2, no. 2, doi:doi:10.1371/journal.pbio.0020007, page E7, XP008154100 DOI: http://dx.doi.org/10.1371/journal.pbio.0020007 | - VAN DE VIJVER, M.J. ET AL., "A gene-expression signature as a predictor of survival in breast cancer", N ENGL J MED, (2002), vol. 347, no. 25, doi:doi:10.1056/NEJMoa021967, pages 1999 - 2009, XP008032093 DOI: http://dx.doi.org/10.1056/NEJMoa021967 | - VAN 'T VEER, L.J. ET AL., "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, (2002), vol. 415, no. 6871, doi:doi:10.1038/415530a, pages 530 - 536, XP008138701 DOI: http://dx.doi.org/10.1038/415530a | - WANG, Y. ET AL., "Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer", LANCET, (2005), vol. 365, no. 9460, doi:doi:10.1016/S0140-6736(05)70933-8, pages 671 - 679, XP002713581 DOI: http://dx.doi.org/10.1016/S0140-6736(05)70933-8 | - BUYSE, M. ET AL., "Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer", J NATL CANCER INST, (2006), vol. 98, no. 17, pages 1183 - 92 | - PAIK, S., "Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early-stage breast cancer treated with tamoxifen", ONCOLOGIST, (2007), vol. 12, no. 6, doi:doi:10.1634/theoncologist.12-6-631, pages 631 - 635, XP002566234 DOI: http://dx.doi.org/10.1634/theoncologist.12-6-631 | - PAIK, S. ET AL., "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer", N ENGL J MED, (2004), vol. 351, no. 27, pages 2817 - 2826, XP002578486 | - SOTIRIOU, C. ET AL., "Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis", J NATL CANCER INST, (2006), vol. 98, no. 4, doi:doi:10.1093/jnci/djj052, pages 262 - 72, XP002490627 DOI: http://dx.doi.org/10.1093/jnci/djj052 | - PAWITAN, Y. ET AL., "Gene expression profiling spares early-stage breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.", BREAST CANCER RES, (2005), vol. 7, no. 6, pages R953 - 964 | - MILLER, L.D. ET AL., "An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.", PROC NATL ACADSCI USA, (2005), vol. 102, no. 38, doi:doi:10.1073/pnas.0506230102, pages 13550 - 13555, XP008155357 DOI: http://dx.doi.org/10.1073/pnas.0506230102 | - BILD, A.H. ET AL., "Oncogenic pathway signatures in human cancers as a guide to targeted therapies", NATURE, (2006), vol. 439, no. 7074, doi:doi:10.1038/nature04296, pages 353 - 357, XP002460134 DOI: http://dx.doi.org/10.1038/nature04296 | - TESCHENDORFF, A.E. ET AL., "A consensus prognostic gene expression classifier for ER positive breast cancer", GENOME BIOL, (2006), vol. 7, no. 10, doi:doi:10.1186/gb-2006-7-10-r101, page R101, XP021027290 DOI: http://dx.doi.org/10.1186/gb-2006-7-10-r101 | - DESMEDT, C. ET AL., "Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series", CLIN CANCER RES, (2007), vol. 13, no. 11, doi:doi:10.1158/1078-0432.CCR-06-2765, pages 3207 - 3214, XP055003155 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-06-2765 | - VAN DE VIJVER, M.J. ET AL., "A gene-expression signature as a predictor of survival in breast cancer.", N ENGL J MED, (2002), vol. 347, no. 25, doi:doi:10.1056/NEJMoa021967, pages 1999 - 2009, XP008032093 DOI: http://dx.doi.org/10.1056/NEJMoa021967 | - HALE; MARHAM, THE HARPER COLLINS DICTIONARY OF BIOLOGY | - DEUTSCHER, M., Guide to Protein Purification Methods Enzymology, ACADEMIC PRESS. INC., (1990), vol. 182 | - RUPP; LOCKER, LAB INVEST., (1987), vol. 56, page A67 | - DE ANDRES ET AL., BIOTECHNIQUES, (1995), vol. 18, page 42044 | - HELD ET AL., GENOME RESEARCH, (1996), vol. 6, pages 986 - 994 | - T.E. GODFREY ET AL., J. MOLEC. DIAGNOSTICS, (2000), vol. 2, pages 84 - 91 | - K. SPECHT ET AL., AM. J. PATHOL., (2001), vol. 158, pages 419 - 29 |